Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Zoetis Inc.'s published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $32.9B | |
|---|---|---|
| Revenue (ttm) | 9.5B | |
| Net income (ttm) | 2.6B | |
| EPS (ttm) | $6.13 | |
| Shares out | 413.2M | |
| P/E (trailing) | 12.7x | |
| P/E (forward) | 12.0x | |
| Dividend | $2.12 (2.73%) | |
| Volume | 2,035,417 | |
| Beta | 0.74 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $7.78B | $8.08B | $8.54B | $9.26B | $9.47B | +5.0% |
| Gross profit | $5.31B | $5.48B | $5.83B | $6.40B | $6.67B | +5.9% |
| Operating income | $2.72B | $2.89B | $3.19B | $3.38B | $3.58B | +7.1% |
| Net income | $2.04B | $2.11B | $2.34B | $2.49B | $2.67B | +7.0% |
| EPS (diluted) | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 | +9.0% |
| EBITDA | $3.17B | $3.36B | $3.69B | $3.87B | $4.07B | +6.4% |
| R&D | $508.0M | $539.0M | $614.0M | $686.0M | $698.0M | +8.3% |
| SG&A | $2.00B | $2.01B | $2.15B | $2.32B | $2.38B | +4.4% |
Recent company headlines from major financial publishers.
In the Bull scenario, veterinary clinic foot traffic rebounds swiftly while international uptake of novel pain monoclonal antibodies Lenivia and Portela exceeds expectations. Dermatology pricing remains resilient as veterinary switching barriers limit competitor share gains. Operating margins expand through operating leverage, and active share repurchases drive sustained compound EPS growth annually.
In the Base scenario, FY2026 revenue reflects the reset guidance range ($9.12B to $9.32B) with EPS of $6.21, before accelerating to 2.51% revenue growth and $6.52 EPS in FY2027. Operating margins normalize to 38.5% by FY2030, while free cash flow generation enables sustained share count reduction of ~1% per year.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.7% | $104 | $107 | $110 | $114 | $117 |
| 8.2% | $97.3 | $99.5 | $102 | $105 | $108 |
| 8.7% | $91.6 | $93.4 | $95.5 | $97.7 | $100 |
| 9.2% | $86.7 | $88.2 | $89.9 | $91.7 | $93.8 |
| 9.7% | $82.4 | $83.7 | $85.1 | $86.7 | $88.3 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
